Charlotte's Web unveils Brightside – precision -formulated approach to hemp-derived THC
Charlotte's Web (TSX:CWEB) has launched of Brightside, a new line of low-dose THC gummies
Each gummy is crafted in cGMP-certified facilities and powered by TiME INFUSION rapid onset technology, delivering effects in just five to 15 minutes
Each gummy is dosed to provide a balanced, elevated experience without overwhelming effects, making Brightside an ideal entry point for THC-curious consumers
Charlotte's Web stock (TSX:CWEB) last traded at $0.13
Charlotte's Web (TSX:CWEB), a pioneer in hemp-derived wellness, has announced the launch of Brightside, a new line of low-dose THC gummies designed to support daily rituals with purpose and precision. This innovative product line marks a bold step into the evolving THC wellness space, offering consumers a mindful, measured approach to cannabis.
Each gummy is crafted in cGMP-certified facilities and powered by TiME INFUSION rapid onset technology, delivering effects in just five to 15 minutes—dramatically faster than traditional edibles.
The Brightside lineup includes three targeted formulations:
Rest and relax : A microdose of THC paired with CBD helps melt away tension and promote calm—ideal for unwinding without the hangover.
: A microdose of THC paired with CBD helps melt away tension and promote calm—ideal for unwinding without the hangover. Focus and flow : Designed to sharpen the mind and eliminate distractions, this blend of THC, CBD, and CBG supports productivity and creativity.
: Designed to sharpen the mind and eliminate distractions, this blend of THC, CBD, and CBG supports productivity and creativity. Relieve and ease: A soothing mix of THC, CBD, CBC, and CBG targets soreness and everyday aches, helping users get back to what they love.
Each gummy is dosed to provide a balanced, elevated experience without overwhelming effects, making Brightside an ideal entry point for THC-curious consumers and wellness enthusiasts alike.
'Brightside is for anyone who's ever wondered if hemp THC could fit into their wellness routine—but didn't know where to start. Brightside represents our strategic response to growing consumer demand for precision wellness solutions that integrate THC,' Bill Morachnick, CEO of Charlotte's Web CEO said in a news release. 'We've leveraged advanced delivery technology and thoughtful formulations to create a product that's not only fast-acting and consistent, but also rooted in our commitment to safety, transparency, and evidence-based wellness. It's a smarter way to explore THC—designed for those who want to feel better with controlled experiences.'
About Charlotte's Web Holdings
Charlotte's Web specializes in wellness products made from hemp extracts including CBD and CBN. The company is the official CBD provider of Major League Baseball and the Premier Lacrosse League.
Charlotte's Web stock (TSX:CWEB) last traded at $0.13 and though it is up 4.00 per cent since the year began, it has lost 45.83 per cent since this time last year.
Join the discussion: Find out what everybody's saying about this cannabis stock's autism drug candidate on the Charlotte's Web Holdings Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
Parkland Corporation Announces Execution of Supplemental Indentures for Senior Notes in Connection with the Consent Solicitations
CALGARY, AB, June 20, 2025 /CNW/ - Parkland Corporation (TSX: PKI) ("Parkland") today announced that in connection with the successful completion of its previously announced consent solicitations, Parkland, the applicable Guarantors and the applicable trustees have executed supplemental indentures (the "Supplemental Indentures") to amend the indentures (the "Indentures") governing the notes listed below (the "Notes"). The consent solicitations were made in connection with Parkland's definitive agreement whereby Sunoco LP ("Sunoco") will acquire the issued and outstanding common shares of Parkland (the "Transaction"), which was previously announced on May 5, 2025. The Supplemental Indentures amended the Indentures by (collectively, the "COC Amendments"): (a) eliminating Parkland's potential obligation under such Indenture to make a "Change of Control Offer" (as defined in such Indenture) as a result of the Transaction; and (b) amending the defined term "Change of Control" in such Indenture to provide that Sunoco and its affiliates will be "Qualified Owners" of Parkland. The Supplemental Indentures became effective upon their execution and are binding on all Holders, as defined in that certain consent solicitation statement issued on May 27, 2025 (the "Consent Solicitation Statement"), including those who did not deliver a consent at or prior to the Expiration Date, as defined in the Consent Solicitation Statement. The COC Amendments will cease to become operative if the Transaction is not consummated or if the applicable consent fees are not paid to the applicable depositary or tabulation agent. This press release is for informational purposes only and does not amend the consent solicitations, which have expired and were made solely on the terms and subject to the conditions set forth in the consent solicitation statement. Further, this press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other securities. Please refer to the earlier press releases dated May 27, 2025 and June 10, 2025, in connection with the consent solicitations for more information. Forward-Looking Statements Certain statements contained herein constitute forward-looking information and statements (collectively, "forward-looking statements"). When used in this news release, the words "believes", "expects", "expected", "will", "plan", "intends", "target", "would", "seek", "could", "projects", "projected", "anticipates", "estimates", "continues" and similar expressions are intended to identify forward-looking statements. In particular, this news release contains forward-looking statements with respect to, among other things, the Transaction. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. These forward-looking statements speak only as of the date hereof. Parkland does not undertake any obligations to publicly update or revise any forward-looking statements except as required by securities laws. Without limiting the generality of the foregoing, forward-looking statements contained in this press release specifically include statements regarding the consummation of the Transaction. Actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks, assumptions and uncertainties. For more information, please see the risks and uncertainties described under the headings "Cautionary Statement Regarding Forward-Looking Information" and "Risk Factors" in Parkland's current Annual Information Form dated March 5, 2025, and under the headings "Forward-Looking Information" and "Risk Factors" included in the Q1 2025 Management's Discussion and Analysis dated May 5, 2025, each as filed on SEDAR+ and available on Parkland's website at The forward-looking statements contained herein are expressly qualified by this cautionary statement. About Parkland Corporation Parkland is a leading international fuel distributor, marketer, and convenience retailer with safe and reliable operations in 26 countries across the Americas. Our retail network meets the fuel and convenience needs of everyday consumers. Our commercial operations provide businesses with fuel to operate, complete projects and better serve their customers. In addition to meeting our customers' needs for essential fuels, Parkland provides a range of choices to help them lower their environmental impact, including manufacturing and blending renewable fuels, ultra-fast EV charging, a variety of solutions for carbon credits and renewables, and solar power. With approximately 4,000 retail and commercial locations across Canada, the United States and the Caribbean region, we have developed supply, distribution and trading capabilities to accelerate growth and business performance.
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
S&P/TSX composite ends lower, U.S. stock markets mixed
TORONTO – Canada's main stock index lost steam through the trading day on Friday to close lower, while U.S. stock markets were mixed. The S&P/TSX composite index was down 8.43 points at 26,497.57. In New York, the Dow Jones industrial average was up 35.16 points at 42,206.82. The S&P 500 index was down 13.03 points at 5,967.84, while the Nasdaq composite was down 98.86 points at 19,447.41. The Canadian dollar traded for 72.84 cents US compared with 72.87 cents US on Thursday. The August crude oil contract was up 34 cents US at US$73.84 per barrel and the July natural gas contract was down 14 cents US at US$3.85 per mmBTU. The August gold contract was down US$22.40 at US$3,385.70 an ounce and the July copper contract was down two cents US at US$4.83 a pound. This report by The Canadian Press was first published June 20, 2025. Companies in this story: (TSX: GSPTSE, TSX: CADUSD)
Cision Canada
8 hours ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
